Status: Enrolling
20172754
GUIDE HF - to demonstrate effectiveness of the CardioMEMS HF System in an expanded patient population including heart failure patients outside of the present indication, but at risk for future Heart failure events or mortality.
The purpose of this research study is to evaluate a heart pressure sensor called the CardioMEMS™ PA Sensor (referred to as “the device”) within the CardioMEMS™ HF System. This small sensor is implanted into the heart on the tip of a catheter and through a vein. It is then threaded up to the heart. The CardioMEMS™ HF System includes the device, an implanted pressure sensor. It takes a daily reading of the pulmonary artery pressure, which reflects the pressures within the heart. The pulmonary artery pressure reading is sent to a secure website that the study doctor can see to help him/her adjust treatment (usually changes in medications). Ideally, this is to be done before the symptoms get too serious.
Principle Investigator: Dr. Robert Mohapatra, M.D
Contact for Participation in this study:
Marisa Brown
Clinical Research Coordinator
856-3551226
mbrown3@virtua.org
Office Location:
Virtua Cardiology Cherry Hill
1 Brace Road Suite H -1
Cherry Hill, NJ08034
Status: Enrolling
20180259
AEGIS - Phase 3 study to investigate the Efficacy and Safety of CSL112 (Apolipoprotein) in subjects with ACS (STEMI/NSTEMI). Double blind, randomized with Albumin Placebo
AEGIS - Phase 3 study to investigate the Efficacy and Safety of CSL112 (Apolipoprotein) in subjects with ACS (STEMI/NSTEMI). Double blind, randomized with Albumin Placebo
Principle Investigator: Vijayendra Verma, M.D.
Contact for Participation in this study:
Donna Hoopes
Clinical Research Coordinator
856-355-1206
dhoopes@virtua.org
Office Location:
Virtua Health Our Lady of Lourdes
1600 Haddon Ave
Camden, NJ08103
Status: Enrolling
20190741
PARAGLIDE - 12 week study to evaluate the effect of Sacubatril/Valsartan (LCZ696/Entresto) versus Valsartan on changes in NT-proBNP and safety and tolerability of in-hospital initiation of LCZ696/Entresto compared to Valsartan in HFpEF patients with acute decompensated heart failure
PARAGLIDE - 12 week study to evaluate the effect of Sacubatril/Valsartan (LCZ696/Entresto) versus Valsartan on changes in NT-proBNP and safety and tolerability of in-hospital initiation of LCZ696/Entresto compared to Valsartan in HFpEF patients with acute decompensated heart failure
Principle Investigator: Robert Mohapatra, M.D.
Contact for Participation in this study:
Donna Hoopes
Clinical Research Coordinator
856-355-1206
dhoopes@virtua.org
Office Location:
Virtua Health Our Lady of Lourdes
1600 Haddon Ave
Camden, NJ08103
Status: Enrolling
MDT 19005
The ALLEVIATE-HF study is a prospective, randomized, controlled, blinded, multi-site, interventional, investigational device exemption (IDE) pivotal study. The study utilizes the market released Reveal LINQ™ Insertable Cardiac Monitor (ICM) with an investigational software download, combined with a clinical medication plan. The Reveal LINQ ICM is a small, leadless device that is inserted under the skin of the chest, that continuously monitors a patient’s heart rhythm and records any unusual heart rhythms. The purpose of the study is to demonstrate the safety and effectiveness of a patient management pathway that utilizes an integrated device diagnostic-based risk stratification algorithm to guide patient care in patients with NYHA class II and III heart failure, and to demonstrate the safety of the Reveal LINQ system and procedure in patients with heart failure
Principle Investigator: Darius Sholevar M.D.
Contact for Participation in this study:
Kristin Broderick
Clinical Research Coordinator
856-355-1231
kbroderick@virtua.org
Office Location:
Virtua Cardiology Cherry Hill
1 Brace Road Suite H -1
Cherry Hill, NJ08034
Status: Enrolling
MDT16028
EV-ICD - The main purpose of the EV ICD Pivotal study is to demonstrate safety and efficacy of the EV ICD System. The Medtronic EV ICD System (defibrillator and lead) is indicated for the automated treatment of patients who have experienced, or are at significant risk of developing, life threatening ventricular tachy-arrhythmias.
This study involves clinical research because you have or may experience abnormal heart rhythms and your doctor recommends that you undergo a medical procedure to implant a device called an implantable cardioverter defibrillator (ICD). An ICD is a device that monitors and treats abnormal heart rhythms. This study is testing a new treatment for abnormal heart rhythms, called the Medtronic Extravascular (EV ICD) system
Principle Investigator: Darius Sholevar, M.D.
Contact for Participation in this study:
Marisa Brown
Clinical Research Coordinator
856-3551226
mbrown3@virtua.org
Office Location:
Virtua Health Our Lady of Lourdes
1600 Haddon Ave
Camden, NJ08103
Status: Enrolling
Pro 00034564
ORION Double blind, Randomized, Placebo-Controlled trial Assessing the Effects of Inclisiran on Clinical Outcomes Among people with Atherosclerotic Cardiovascular Disease
ORION Double blind, Randomized, Placebo-Controlled trial Assessing the Effects of Inclisiran on Clinical Outcomes Among people with Atherosclerotic Cardiovascular Disease
Principle Investigator: DR. Scott Gabler, M.D.
Contact for Participation in this study:
Kristin Broderick
Clinical Research Coordinator
856-355-1231
kbroderick@virtua.org
Office Location:
Virtua Cardiology Voorhees
1105 Laurel Oak Road
Voorhees, NJ08043